Suppr超能文献

肾移植术后胰腺-肾联合移植中活体和尸体供肾者的胰腺结局比较。

Pancreas outcomes between living and deceased kidney donor in pancreas after kidney transplantation patients.

机构信息

Renal Transplant Unit, Nephrology and Kidney Transplantation Department, Hospital Clinic, Barcelona, Spain.

Laboratori Experimental de Nefrologia I Trasplantament (LENIT), CRB CELLEX, Fundació Clínic, IDIBAPS, Barcelona, Spain.

出版信息

Nephrol Dial Transplant. 2018 Nov 1;33(11):2052-2059. doi: 10.1093/ndt/gfy133.

Abstract

BACKGROUND

Pancreas outcomes in pancreas after kidney transplantation (PAK) patients have been reported as being inferior to those of patients who receive simultaneous pancreas and kidney transplantation (SPK). The influence of the kidney donor (i.e. living versus deceased) has never been previously addressed.

METHODS

We retrospectively analysed all pancreas transplants performed in a single centre since 2007 and compared the outcomes between those patients who had previously received a living-donor kidney transplant (pancreas transplantation after living-donor kidney transplantation, PAldK; n = 18) or a deceased-donor kidney transplant (pancreas transplantation after deceased-donor kidney transplantation, PAddK; n = 28), using SPK (n = 139) recipients as a reference.

RESULTS

Pancreas survival was similar between all groups, but inferior for PAldK when including only those with a functioning graft at day 90 post-transplantation (P = 0.004). Pancreas acute rejection was significantly increased in PAldK (67%; 1.8 ± 1.4 episodes/graft) when compared with PAddK (25%) and SPK (32%) (P < 0.05) patients. In a multivariate Cox regression model including known risk factors for pancreas rejection, PAldK was the only predictor of acute rejection (hazard ratio 6.82, 95% confidence interval 1.51-30.70, P < 0.05). No association was found between donor-recipient HLA mismatches and graft rejection. Repeated HLA mismatches between kidney and pancreas donors (0 versus 1-6) did not correlate with pancreas graft rejection or survival in either PAK transplantation group (P > 0.05).

CONCLUSION

Pancreas graft outcomes are worse for PAldK when compared with PAddK and SPK patients.

摘要

背景

在胰腺肾联合移植(PAK)患者中,胰腺的结果不如同时接受胰腺和肾联合移植(SPK)的患者。但肾供体(活体与尸肾)的影响以前从未被提及过。

方法

我们回顾性分析了自 2007 年以来在一个中心进行的所有胰腺移植,并比较了先前接受过活体供肾移植(胰腺移植后活体供肾,PAldK;n=18)或尸肾移植(胰腺移植后尸肾,PAddK;n=28)的患者与 SPK(n=139)患者的结果。

结果

各组之间胰腺存活率相似,但在仅包括移植后 90 天内功能移植物的患者中,PAldK 的存活率较低(P=0.004)。与 PAddK(25%)和 SPK(32%)患者相比,PAldK 的胰腺急性排斥反应显著增加(67%;1.8±1.4 次/移植物)(P<0.05)。在包括已知胰腺排斥危险因素的多变量 Cox 回归模型中,PAldK 是急性排斥的唯一预测因子(风险比 6.82,95%置信区间 1.51-30.70,P<0.05)。供体-受者 HLA 错配与移植物排斥之间没有关联。肾和胰腺供体之间重复的 HLA 错配(0 对 1-6)与 PAK 移植组中任何一组的胰腺移植物排斥或存活率均无相关性(P>0.05)。

结论

与 PAddK 和 SPK 患者相比,PAldK 的胰腺移植物结果更差。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验